Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.34 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2102582 | 1.00 | RBP4 (0.34) | RBP4CALCRLKMT2ACYP2C9CYP2C19 | |
| SCHEMBL2100515 | 0.88 | GPR119 (0.44) | — | |
| SCHEMBL2100512 | 0.88 | GPR119 (0.44) | — | |
| SCHEMBL4076113 | 0.84 | ABCB1 (0.33) | MAPK14 | |
| SCHEMBL2103870 | 0.82 | RBP4 (0.40) | RBP4KMT2ACYP2C19CHRM4 | |
| SCHEMBL2103867 | 0.82 | RBP4 (0.40) | RBP4KMT2ACYP2C19CHRM4 | |
| SCHEMBL2103228 | 0.78 | ERN1 (0.41) | RBP4KMT2ACYP2C9CYP2C19MAPK14 | |
| SCHEMBL2606286 | 0.77 | GPR119 (0.42) | — | |
| SCHEMBL3466609 | 0.74 | HSD11B1 (0.44) | RBP4KMT2ANOTUM | |
| SCHEMBL2101060 | 0.71 | MLYCD (0.36) | KMT2ACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163737-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, GRPR | RBP4 3048/4885CALCRL 1/4885KMT2A 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.